Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune... see more

TSX:ONC - Post Discussion

Oncolytics Biotech Inc > Regarding the transcript…lots of good & great stuff
View:
Post by canadafan on May 07, 2023 12:07pm

Regarding the transcript…lots of good & great stuff

Regarding the transcript, FYI, it worth a listen & can also be found on Onc web site.
regarding the yahoo board.
that site is extremely biased, towards the negative.
Many times I have been prohibited from posting, or my posts just disappear.
All the while the moderator allows the backbiting, name calling & general gibberish.
All known as Ad Hominem attacks.
Regretably that site has been reduced, to grade school level ...wall writing.
Any posts of substance ( technical discussions re Pelareorep & opportunities), are avoided.
That, said, imho the Q1 cc, was informative, upbeat & has gained more attention than the other last 3 combined.
RBC still has a $6 target , with $18 upside....assuming more data, or partnership.
Translated....after ASCO , & assuming phase 3 plans are put in place, they will be increasing their SP targets.
They are the most conservative.
It will be interesting to see what the two newest analysts come out with, as a new SP target?
I agree 100% with the expectations of a buyout price. Being $2billion +.
The analysts don't discuss " take over or buyouts" 
They only use projections of potential product sales, discounted for risk & time from actual market.
The next " event" will be pre- publication of the ASCO abstract poster. That is 25th of this month.
followed by a flurry of activity.
The oral ASCO presentation, followed by a KOL presentation, a day or so later.
exciting times ahead....it certainly has been a long wait.
Comment by Geneman2004 on May 07, 2023 1:02pm
From the beginning, the future share price has always depended upon safety and efficacy. The company has a long history of safety data from animal studies as well as intra-tumoral and IV delivery. To deliver on the promise of clinical efficacy, the BRACELET results have to complement IND213. This provides the foundation for a true registration trial in ER+ mBC. Having two controlled trials with ...more  
Comment by Noteable on May 07, 2023 1:06pm
Agreed 
Comment by Noteable on May 07, 2023 2:50pm
Relevant excerpt of ONCY's Earnings Call opening remarks on May 05, 2023:  Matt Coffey Thanks, Jon. It's my pleasure to provide an overview of our recent highlights and outlook for the coming months. I will start with the exciting news that came out just last week when we announced the results from our randomized BRACELET-1 trial in HR-positive/HER2-negative metastatic breast cancer ...more  
Comment by Noteable on May 07, 2023 8:02pm
Validating ppelareorep's single agent activity sets pelareorep up for subsequent approval in combination with immune checkpoint inhibitors,  CAR-T therapy, bispecifics and antibody drug conjugates, and small molecule drugs like PARP and CDK4/6 inhibitors.
Comment by Noteable on May 10, 2023 11:38am
Some apparently had missed the point that validating pelareorep's single agent activity sets pelareorep up for subsequent approval in combination with immune checkpoint inhibitors,  CAR-T therapy, bispecifics and antibody drug conjugates, and small molecule drugs like PARP and CDK4/6 inhibitors.
Comment by lonc17 on May 07, 2023 1:39pm
"If the BRACELET results are unambigously positive, the negotiations for a Biotech/Pharma partner will accelerate and broaden" That is a very big IF.    In all my years watching ONC (20+) and witnessing real-time every PR announcing data from a trial (30+?), not once have I seen results that are unambigoulsy positive.  In fact, ONC has a history of muddying the waters ...more  
Comment by inthno on May 07, 2023 8:11pm
I am kinda wondering how AN might fit into all of this as to whether they will just run a concurrent trial incorporating the results from Aware1 and Bracelet. It will be interesting to see how much empahsis will be put on the biomarkers as there was hardly any mention of it in the quarterly cc when talking about the trial design so am hoping that onc will provide more clarity once asco results are ...more  
Comment by inthno on May 07, 2023 8:42pm
Further on in the AN document I found the following and am curious of the relevance. We are responsible for developing the Oncolytics Licensed Product for use in the Oncolytics Licensed Field in the Oncolytics Agreement Territory in accordance with the terms of the Oncolytics Agreement. The parties have agreed on an initial development plan for a term of three years ended in June 2022 with respect ...more  
Comment by westcoast1000 on May 07, 2023 11:19pm
inthno, Could you clarify how you learned that AN wanted to start a trial last year? That seems important  in my view.  Thanks
Comment by inthno on May 08, 2023 12:35am
Hello Westcoast and this is an exerpt from a document that I was able to obtain through a friend through the Hong Kong securities. Originally AN was going to run the phase 3 trial in 2022 as this was stated in their original documents from Hong Kong. We received the approval from the NMPA in February 2019 for our initiation of an open-label, randomized, multi-center, global phase III clinical ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities